2021 / 02

Next Paper
DOI: 10.24075/brsmu.2021.011

OPINION

Compulsory licensing in pharmaceutical industry: current state of affairs and prospects

Gaydin TY1,2, Rozhnova SA1
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Lomonosov Moscow State University, Moscow, Russia

Correspondence should be addressed: Timofey Yu. Gaydin
Ostrovityanova, 1, Moscow, 117997; ur.usm.noce@a81ytag

About paper

Author contribution: Gaydin TY analyzed the literature, conducted the study and wrote the draft of the manuscript; Rozhnova SA planned and conducted the study, analyzed the literature and wrote the draft of the manuscript

Received: 2021-02-09 Accepted: 2021-02-22 Published online: 2021-03-09
|
Fig. The results of the analysis of external political, economic, social and technological factors that impact the decision to launch production of lenalidomide-based generic drugs
Table 1. Examples of using CL in the pharmaceutical sector
Table 2. Comparison of maximum wholesale prices for the original drug lenalidomide and its generic (from https://grls.rosminzdrav.ru/)
Table 3. The analysis of external political, economic, social, and technological factors (PEST analysis) that might influence the decision to issue a compulsory license for the generic lenalidomide drug
Note: R&D — research and development.